drugset / Trial / NCT04308811

Autologous Platelet-Rich Plasma in the Management of Asherman Syndrome

NCT04308811

Phase 2 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to find out the benefit of the platelet-rich plasma in preventing reformation of intrauterine adhesions after adhesiolysis in cases of Asherman syndrome

Timeline

Start
2019-08-10
Primary completion
2020-02-20
Completion
2020-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified Other
Subject amniotic membrane graft Unknown Other

Indications